Loading your page…
Journal of pain research
By Gan X, Wang K, Lu D and 4 others.
Neuropathic pain involves complex neuroimmune interactions across the somatosensory nervous system, yet a comprehensive multi-tissue cellular landscape remains lacking.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
We integrated single-cell RNA sequencing data from the sciatic nerve (SN), dorsal root ganglion (DRG), and spinal cord (SC) of spared nerve injury (SNI) mice. The therapeutic potential of the selective CCR2 antagonist RS504393 was evaluated in vivo.
Macrophages dominated the injured SN (40.5%), exhibiting an inferred transcriptional shift from a resident-like Mrc1+ phenotype toward proinflammatory Ccl2+/Spp1+ subtypes. Injury elevated glycolytic activity in SN macrophages and spinal microglia, but suppressed metabolism in DRG neurons. Cell-cell communication analysis predicted enhanced CCL2-CCR2 signaling from peripheral macrophages to sensory neurons in the Pain group. In vivo, RS504393 administration significantly alleviated mechanical and thermal hypersensitivity, reduced spinal inflammatory infiltration, and suppressed microglial activation.
This study provides an integrated multi-tissue single-cell analysis of neuropathic pain and highlights the CCL2-CCR2 signaling pathway as a potential non-opioid therapeutic target at the peripheral neuroimmune interface, with pharmacological evidence suggesting downstream central effects.
Published in Journal of pain research. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
